Lockerman Financial Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$291K Sell
243
-5
-2% -$5.11K 0.45% 65
2026
Q1
$228K Sell
248
-1
-0.4% -$1.01K 0.41% 80
2025
Q4
$267K Sell
249
-368
-60% -$352K 0.51% 65
2025
Q3
$470K Sell
617
-4
-0.6% -$2.98K 0.59% 44
2025
Q2
$484K Sell
621
-1
-0.2% -$777 0.65% 43
2025
Q1
$514K Buy
622
+3
+0.5% +$2.5K 0.78% 30
2024
Q4
$478K Sell
619
-17
-3% -$14.1K 0.81% 33
2024
Q3
$563K Buy
636
+22
+4% +$19.8K 0.95% 31
2024
Q2
$556K Sell
614
-1
-0.2% -$800 1.01% 28
2024
Q1
$479K Sell
615
-26
-4% -$18.5K 0.92% 31
2023
Q4
$374K Sell
641
-10
-2% -$5.84K 0.86% 36
2023
Q3
$350K Buy
651
+11
+2% +$5.67K 0.94% 36
2023
Q2
$300K Sell
640
-66
-9% -$27.7K 0.83% 38
2023
Q1
$242K Sell
706
-34
-5% -$11.5K 0.67% 55
2022
Q4
$271K Sell
740
-88
-11% -$31.2K 0.79% 49
2022
Q3
$268K Buy
828
+54
+7% +$17.1K 0.77% 39
2022
Q2
$251K Buy
774
+44
+6% +$13.2K 0.8% 45
2022
Q1
$209K Buy
+730
New +$188K 0.56% 70

Other funds holding LLY

Lockerman Financial Group's LLY Position: Q2 2026 in Review

Lockerman Financial Group reduced its Eli Lilly (LLY) stake by 2% in Q2 2026, selling an estimated $5.11K and leaving 243 shares worth $291K. The position accounts for 0.45% of the portfolio, ranked #65.

Lockerman Financial Group first reported a position in LLY in Q1 2022 and has held it in 18 quarters since. The position peaked at $563K in Q3 2024. 4,618 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Lockerman Financial Group held 243 shares of Eli Lilly worth $291K as of Q2 2026.
  • Lockerman Financial Group sold 5 Eli Lilly shares in Q2 2026, an estimated $5.11K.
  • Eli Lilly made up 0.45% of Lockerman Financial Group's portfolio in Q2 2026, its #65 holding.
  • Lockerman Financial Group first reported a position in Eli Lilly in Q1 2022 and has held it in 18 quarters since.
  • Lockerman Financial Group's Eli Lilly position peaked at $563K in Q3 2024.
  • 4,618 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Lockerman Financial Group's 13F filing for Q2 2026, filed 16 Jul 2026.